{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:29:09Z","timestamp":1793744949722,"version":"4.6.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102188","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:34:18Z","timestamp":1787096058000},"page":"102188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An atypical presentation of Pembrolizumab-induced bullous pemphigoid in a patient with uterine serous carcinoma"],"prefix":"10.1016","volume":"67","author":[{"given":"Rachel Y.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Vasavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotonye","family":"Imadojemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie W.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102188_bb0005","doi-asserted-by":"crossref","unstructured":"Asdourian, M. S., Shah, N., Jacoby, T. V., Reynolds, K. L. & Chen, S. T. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. vol. 158 933\u2013941 Preprint at Doi: https:\/\/doi.org\/10.1001\/jamadermatol.2022.1624 (2022).","DOI":"10.1001\/jamadermatol.2022.1624"},{"key":"10.1016\/j.gore.2026.102188_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.gore.2026.102188_bb0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.gore.2026.102188_bb0020","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/JCO.2026.44.16_suppl.5502","article-title":"Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin\/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial","volume":"44","author":"Eskander","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102188_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010638","article-title":"Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events","volume":"13","author":"Khattab","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.gore.2026.102188_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf208","article-title":"Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","volume":"30","author":"Nykaza","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.gore.2026.102188_bb0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series","volume":"192","author":"Planella-Fontanillas","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.gore.2026.102188_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102188_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04172-3","article-title":"The immunophenotype of immune checkpoint-induced bullous pemphigoid: a cohort study","volume":"74","author":"Saffuri","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.gore.2026.102188_bb0050","author":"Schneider"},{"key":"10.1016\/j.gore.2026.102188_bb0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"British J. Dermatology"},{"key":"10.1016\/j.gore.2026.102188_bb0060","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced Cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.gore.2026.102188_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gore.2026.102188_bb0070","article-title":"Efficacy and safety of Dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gore.2026.102188_bb0075","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:02:11Z","timestamp":1793743331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S2352578926001682"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102188","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An atypical presentation of Pembrolizumab-induced bullous pemphigoid in a patient with uterine serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102188"}}